Incidence of chemotherapy-induced nausea and vomiting in Mexico: Healthcare provider predictions versus observed

Current Medical Research and Opinion

Volumn 22, Issue 12, 2006, Pages 2403-2410

  Valle, Aura Erazo ^a   Wisniewski, Tami ^b   Vadillo, Jasmin Isabel Figueroa ^c   Burke, Thomas A ^d   Corona, Roberto Martinez ^e  

^a Hospital 20 de Noviembre   (Mexico)

^b ST JOHN'S UNIVERSITY   (United States)

^c HOSPITAL GENERAL DE MÉXICO   (Mexico)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Hospital Regional C/MF No 1   (Mexico)

Author keywords

Antiemetics; Antineoplastic agents; Nausea, chemically induced; Vomiting, chemically induced

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; GRANISETRON; ONDANSETRON; THIETHYLPERAZINE MALEATE;

ADULT; AGED; CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; INCIDENCE; MALE; MEXICO; MONOTHERAPY; NAUSEA; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; HEALTH PERSONNEL; HUMANS; INCIDENCE; MALE; MEXICO; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; VOMITING;

EID: 33846002327     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X154033     Document Type: Conference Paper

References (26)

1. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005;13:219-27
2. Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 2003;1:46
3. Glaus A, Knipping C, Morant R, et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004;12:708-15
4. Osoba D, Zee B, Warr D, et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5:307-13
5. Osoba D, Zee B, Pater J, et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:116-23
6. O'Brien BJ, Rusthoven J, Rocchi A, et al. Impact of chemotherapy- associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. CMAJ 1993;149:296-302
7. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004;15:526-36
8. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9
9. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 2005;13:80-4
10. National Comprehensive Cancer Network. Antiemesis. Clinical practice guidelines in oncology-v.2.2006. Available from http://www.nccn.org/ professionals/physician_gls/PDF/antiemesis.pdf [Last accessed 7 June 2006]
11. American Society of Health-System Pharmacists.ASHP Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm 1999;56:729-64
12. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 1998;9:811-19
13. Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-95
14. Carelle N, Piotto E, Bellanger A, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155-63
15. de Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-61
16. Hofman M, Morrow GR, Roscoe JA, et al. Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center - Community Clinical Oncology Program study of 938 patients from community practices. Cancer 2004;101:851-7
17. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-8
18. Liau CT, Chu NM, Liu HE, et al. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes. Support Care Cancer 2005;13:277-86
19. Jordan K. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy. Onkologie 2006;29:39-43
20. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy-and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-8
21. Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2005;13:85-96
22. Herrstedt J, Aapro MS, Roila F, Kataja W. ESMO Minimum Clinical Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 2005;16 (Suppl 1):i77-9
23. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47
24. Aguilar EA, Figueiras MC, Cortes-Funes H, et al. Clinical practice guidelines on antiemetics in oncology. Expert Rev Anticancer Ther 2005;5:963-72
25. De Angelis V, Roila F, Sabbatini R, et al. Cancer chemotherapy-induced delayed emesis: antiemetic prescriptions in clinical practice [abstract]. Proc Am Soc Clin Oncol 2003;22:739
26. Rubenstein EB, Litke SE, Jose MA. Chemotherapy-induced nausea and emesis in the 5HT3 era: a national survey of hematologists/oncologists [abstract]. Proc Am Soc Clin Oncol 2002;21:260b